Drug intelligence / Profile preview

MG56 Mannosylated 5000

Development stage: Phase 2
Administration: Sublingual

Overview

MG56 Mannosylated 5000 is a sublingual immunotherapy treatment being investigated for rhinitis/rhinoconjunctivitis against grass pollen allergy. It is administered at a concentration of 5000 mTU/mL as a sublingual therapy, while patients also receive a subcutaneous placebo as part of the study protocol.

Other names: hedgehog acyltransferase-like protein

Targets

MRC1 (Mannose Receptor C-type 1)

Beyond the preview

Go deeper on MG56 Mannosylated 5000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MG56 Mannosylated 5000.

Explore the full profile